DarioHealth Corp.
DRIO Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$3.77
KIRA · Stoqly’s AI analyst, in plain words
- DarioHealth Corp. had $22.4M of revenue in fiscal 2025, down 17.3% on the year before. Over five years, revenue changed +24.2% a year on average.
- Its operating margin was −163.9%, up 49.6 pts: of every 100 in sales, about −164 is left after running the business.
- DarioHealth Corp. lost $41.7M in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 19.2% a year.
- Free cash flow was −$26.1M in fiscal 2025, −116.7% of revenue.
- DarioHealth Corp. owes $4.7M more than it holds in cash.
Market cap
$35.2M
P/E
0.6x
Revenue
$22.4M
Net income
−$41.7M
Free cash flow
−$26.1M
Operating margin
−163.9%
DarioHealth Corp. in 30 seconds · fiscal 2025
Are sales growing?
−17.3%
No. Sales fell 17.3% last year.
Does it make a profit?
−186.6%
No. It lost money last year.
Does profit turn into cash?
−116.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
0.6x
One share costs 0.6 times its yearly profit per share.
What DarioHealth Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- DarioHealth Corp.
- CIK
- 0001533998
DarioHealth Corp. · DRIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $20.5M | $27.7M | $20.4M | $27.0M | $22.4M |
| Revenue growth | 170.8% | 34.8% | −26.4% | 32.9% | −17.3% |
| Gross margin | 19.3% | 34.9% | 29.4% | 49.1% | 56.6% |
| Operating margin | −372.9% | −205.4% | −276.1% | −213.6% | −163.9% |
| Net income | −$76.8M | −$62.2M | −$59.4M | −$42.7M | −$41.7M |
| Net margin | −374.2% | −224.9% | −292.0% | −158.1% | −186.6% |
| Diluted EPS | $4.07 | $2.54 | $1.93 | $12.27 | $10.12 |
| Cash | |||||
| Cash from operations | −$50.4M | −$47.8M | −$30.4M | −$38.6M | −$25.9M |
| Capital expenditure | $0.3M | $0.4M | $0.6M | $0.1M | $0.1M |
| Free cash flow | −$50.7M | −$48.3M | −$31.0M | −$38.7M | −$26.1M |
| FCF margin | −247.0% | −174.6% | −152.1% | −143.1% | −116.7% |
| Share buybacks | — | $0.1M | — | — | — |
| Share count change | 178.2% | 42.5% | 20.0% | −91.4% | 62.4% |
| Debt and strength | |||||
| Cash and short-term investments | $35.8M | $49.4M | $36.8M | $27.8M | $26.0M |
| Debt incl. finance leases | $0.0M | $35.8M | $28.5M | $28.9M | $30.7M |
| Shareholders' equity | $85.5M | $80.0M | $58.1M | $72.0M | $67.9M |
| Current ratio | 3.2x | 3.4x | 3.8x | 2.4x | 3.8x |
| Interest coverage | — | −30.3x | — | — | −12.1x |
| Returns and quality | |||||
| Return on capital | −121.5% | −67.6% | −89.0% | −62.3% | −39.9% |
| Return on equity | −135.0% | −75.1% | −86.0% | −65.7% | −59.6% |
| Return on tangible equity | −214.7% | −210.8% | −535.4% | — | — |
| Piotroski F-score | 2 | 5 | 3 | 6 | 3 |
| Altman Z'' | −4.3 | −6.3 | −11.8 | −11.0 | −12.4 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
DarioHealth Corp. · DRIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.77 a share, the company is worth $35.2M: 0.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001533998). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.